EA201992226A1 - Агонисты npra, композиции и их использование - Google Patents
Агонисты npra, композиции и их использованиеInfo
- Publication number
- EA201992226A1 EA201992226A1 EA201992226A EA201992226A EA201992226A1 EA 201992226 A1 EA201992226 A1 EA 201992226A1 EA 201992226 A EA201992226 A EA 201992226A EA 201992226 A EA201992226 A EA 201992226A EA 201992226 A1 EA201992226 A1 EA 201992226A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fatty acyl
- natriuretic peptide
- terminus
- integer
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Abstract
Настоящее изобретение раскрывает производное натрийуретического пептида формулы (I) и композиции, содержащие производное натрийуретического пептида формулы (I),где z представляет собой 1, x представляет собой целое от 2 до 4 и y представляет собой 3; или z представляет собой 0, x представляет собой целое от 0 до 4 и y представляет собой целое от 1 до 3; жирный ацил содержит от 12 до 24 (например, от 12 до 18) атомов углерода; В представляет собой лизин или аргинин; G представляет собой глицин; NP представляет собой натрийуретический пептид; если присутствует (жирный ацил)- ковалентно связывают с N-концом в (B); (жирный ацил)-(B)- ковалентно связывают с N-концом в (G); и (жирный ацил)-(B)-(G)- ковалентно связывают с N-концом в NP. Производное натрийуретического пептида в соответствии с раскрытием и его композиции можно использовать при лечении заболеваний, таких как гипертензия, сосудистый застой и заболевание сердца.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475147P | 2017-03-22 | 2017-03-22 | |
| PCT/US2018/023491 WO2018175534A1 (en) | 2017-03-22 | 2018-03-21 | Npra agonists, compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992226A1 true EA201992226A1 (ru) | 2020-02-12 |
Family
ID=63585777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992226A EA201992226A1 (ru) | 2017-03-22 | 2018-03-21 | Агонисты npra, композиции и их использование |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200017567A1 (ru) |
| EP (1) | EP3601314A4 (ru) |
| JP (2) | JP7126270B2 (ru) |
| KR (1) | KR20190133201A (ru) |
| CN (1) | CN110603260B (ru) |
| AU (1) | AU2018239352A1 (ru) |
| BR (1) | BR112019019720A2 (ru) |
| CA (1) | CA3056433A1 (ru) |
| EA (1) | EA201992226A1 (ru) |
| IL (1) | IL269388A (ru) |
| MX (1) | MX2019010960A (ru) |
| PH (1) | PH12019550163A1 (ru) |
| SG (1) | SG11201908580XA (ru) |
| WO (1) | WO2018175534A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220273669A1 (en) | 2019-05-22 | 2022-09-01 | Merck Sharp Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| US20220281886A1 (en) * | 2019-05-22 | 2022-09-08 | Merck Sharp Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| WO2021252931A2 (en) * | 2020-06-12 | 2021-12-16 | Pharmain Corporation | C-type natriuretic peptides and methods thereof in treating cancer |
| CA3184145A1 (en) * | 2020-06-12 | 2021-12-16 | Pharmain Corporation | C-type natriuretic peptides and methods thereof in treating acute lung injury |
| WO2024086680A2 (en) | 2022-10-21 | 2024-04-25 | Eli Lilly And Company | Long-acting natriuretic peptides and uses thereof |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985722A (en) * | 1973-12-12 | 1976-10-12 | Ajinomoto Co., Inc. | Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins |
| FR2687156B1 (fr) * | 1992-02-12 | 1994-04-01 | Roussel Uclaf | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. |
| CN1062311C (zh) * | 1996-12-27 | 2001-02-21 | 中国医学科学院基础医学研究所 | 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用 |
| US6319503B1 (en) | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| BR0316560A (pt) * | 2002-11-26 | 2005-10-04 | Nobex Corp | Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto |
| WO2008154226A1 (en) * | 2007-06-06 | 2008-12-18 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| AU2008287340A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| CA2705603A1 (en) * | 2007-11-21 | 2009-05-28 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| SI2277890T1 (sl) * | 2008-05-23 | 2016-04-29 | Daiichi Sankyo Company, Limited | Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi |
| US9266939B2 (en) * | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| SG192744A1 (en) * | 2011-02-23 | 2013-09-30 | Madeleine Pharmaceuticals Pty Ltd | Therapeutic method for treating congestive heart failure |
| US20120220528A1 (en) * | 2011-02-25 | 2012-08-30 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
-
2018
- 2018-03-21 SG SG11201908580X patent/SG11201908580XA/en unknown
- 2018-03-21 CA CA3056433A patent/CA3056433A1/en active Pending
- 2018-03-21 EP EP18771099.1A patent/EP3601314A4/en active Pending
- 2018-03-21 KR KR1020197031122A patent/KR20190133201A/ko not_active Application Discontinuation
- 2018-03-21 BR BR112019019720A patent/BR112019019720A2/pt unknown
- 2018-03-21 AU AU2018239352A patent/AU2018239352A1/en active Pending
- 2018-03-21 EA EA201992226A patent/EA201992226A1/ru unknown
- 2018-03-21 JP JP2019551608A patent/JP7126270B2/ja active Active
- 2018-03-21 WO PCT/US2018/023491 patent/WO2018175534A1/en unknown
- 2018-03-21 CN CN201880028963.9A patent/CN110603260B/zh active Active
- 2018-03-21 MX MX2019010960A patent/MX2019010960A/es unknown
-
2019
- 2019-09-12 PH PH12019550163A patent/PH12019550163A1/en unknown
- 2019-09-16 IL IL26938819A patent/IL269388A/en unknown
- 2019-09-20 US US16/577,947 patent/US20200017567A1/en active Pending
-
2022
- 2022-04-22 JP JP2022070710A patent/JP2022090049A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019019720A2 (pt) | 2020-04-28 |
| CN110603260B (zh) | 2023-11-07 |
| CA3056433A1 (en) | 2018-09-27 |
| SG11201908580XA (en) | 2019-10-30 |
| MX2019010960A (es) | 2020-01-20 |
| WO2018175534A1 (en) | 2018-09-27 |
| AU2018239352A1 (en) | 2019-10-10 |
| IL269388A (en) | 2019-11-28 |
| JP2022090049A (ja) | 2022-06-16 |
| CN110603260A (zh) | 2019-12-20 |
| US20200017567A1 (en) | 2020-01-16 |
| PH12019550163A1 (en) | 2020-06-08 |
| KR20190133201A (ko) | 2019-12-02 |
| EP3601314A4 (en) | 2021-01-13 |
| JP7126270B2 (ja) | 2022-08-26 |
| JP2020511494A (ja) | 2020-04-16 |
| EP3601314A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992226A1 (ru) | Агонисты npra, композиции и их использование | |
| CY1118676T1 (el) | Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c) | |
| CO2018000303A2 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| MA41778A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| EA200901459A1 (ru) | Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства | |
| CY1116011T1 (el) | Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει | |
| CO6400235A2 (es) | Tensiactivos reconstituidos que tienen propiedades mejoradas | |
| JP2016512214A5 (ru) | ||
| EA201990839A1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
| EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
| JP2018505146A5 (ru) | ||
| BRPI0609783A8 (pt) | composto, utilização do mesmo, composição farmacêutica ou cosmética, e, utilização cosmética de um composto | |
| EA202090448A1 (ru) | Дигидрооксадиазиноны | |
| EA201691883A1 (ru) | Жидкая композиция, содержащая соединение, нейтрализующее gm-csf | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| EA202092749A1 (ru) | Композиции, содержащие аминокислоты, для применения в предотвращении и лечении заболеваний печени | |
| EA201990560A1 (ru) | Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии | |
| MX2020010520A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas. | |
| EA201790336A1 (ru) | Антитела к ангиопоэтинподобному белку 4 и способы применения | |
| EA201992626A1 (ru) | Способы и композиции для лечения аллергических заболеваний глаз | |
| EA202191446A1 (ru) | Композиции для улучшения сексуальной функции | |
| EA201690056A1 (ru) | ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |